Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA -0.68% 82.2 Delayed Quote.-7.79%
ROCHE HOLDING LTD. 0.62% 211.3 Delayed Quote.-14.81%
ROCHE HOLDING LTD. 1.02% 184.16 Delayed Quote.-13.18%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
06/18MERCK : Data Presented at EAN 2018 Provide Further Insight into the Efficacy of ..
PU
06/16MERCK : Survey Reveals Most Thyroid Disorder Patients Find Road to Diagnosis Lon..
AQ
06/14MERCK : New Findings from Merck KGaA in the Area of Non-Small Cell Lung Cancer R..
AQ
06/14STUDIES FROM MERCK KGAA PROVIDE NEW : Real-world evidence for...
AQ
06/14MERCK : Data on Investigational Cladribine Tablets and Rebif® (interferon beta-1..
PU
06/14MERCK : to retain gene-editing tech despite cancer claims
AQ
06/12MERCK : Says Primary Endpoints Met In Two Phase II Trials For Tepotinib
AQ
06/12MERCK : Darmstadt, Germany Drives Thought Leadership in Ethical Gene Editing
PU
06/12MERCK KGAA : Darmstadt, Germany Provides Update on Tepotinib Phase II Results in..
AQ
06/11MERCK : Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Adva..
PU
More news
News from SeekingAlpha
06/13YOUR DAILY PHARMA SCOOP : Tetraphase Positive Data, MediWound In Phase 3, Allerg.. 
06/133 THINGS IN BIOTECH, JUNE 12 : MET Targeting Gets On Your Radar 
06/11Merck KGaA's tepotinib successful two mid-stage liver cancer studies 
06/07MINING ASCO 2018'S GOLD, PART 13 : Breathe Deep, This Is The Final Chapter 
05/23MERCK KG&A (MKGAY) Presents At 2018 UBS Global Healthcare Conference - Slides.. 
Financials (€)
Sales 2018 14 889 M
EBIT 2018 2 897 M
Net income 2018 2 174 M
Debt 2018 7 414 M
Yield 2018 1,53%
P/E ratio 2018 15,63
P/E ratio 2019 17,43
EV / Sales 2018 1,23x
EV / Sales 2019 1,07x
Capitalization 10 908 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 96,6 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-7.79%12 679
ABBVIE2.96%158 006
KYOWA HAKKO KIRIN CO LTD4.77%12 387
JAZZ PHARMACEUTICALS PLC32.27%10 685
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD67.36%9 897
CONVATEC GROUP5.89%5 669